IL158904A0 - Pirenzepine ophthalmic gel - Google Patents

Pirenzepine ophthalmic gel

Info

Publication number
IL158904A0
IL158904A0 IL15890402A IL15890402A IL158904A0 IL 158904 A0 IL158904 A0 IL 158904A0 IL 15890402 A IL15890402 A IL 15890402A IL 15890402 A IL15890402 A IL 15890402A IL 158904 A0 IL158904 A0 IL 158904A0
Authority
IL
Israel
Prior art keywords
ophthalmic gel
pirenzepine
pirenzepine ophthalmic
gel
ophthalmic
Prior art date
Application number
IL15890402A
Other languages
English (en)
Original Assignee
Valley Forge Pharmaceuticals
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Valley Forge Pharmaceuticals filed Critical Valley Forge Pharmaceuticals
Publication of IL158904A0 publication Critical patent/IL158904A0/xx

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/55131,4-Benzodiazepines, e.g. diazepam or clozapine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/55131,4-Benzodiazepines, e.g. diazepam or clozapine
    • A61K31/55171,4-Benzodiazepines, e.g. diazepam or clozapine condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38Cellulose; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0048Eye, e.g. artificial tears
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • A61P27/10Ophthalmic agents for accommodation disorders, e.g. myopia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
IL15890402A 2001-05-25 2002-05-01 Pirenzepine ophthalmic gel IL158904A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US29373101P 2001-05-25 2001-05-25
PCT/US2002/013823 WO2002096418A1 (en) 2001-05-25 2002-05-01 Pirenzepine ophthalmic gel

Publications (1)

Publication Number Publication Date
IL158904A0 true IL158904A0 (en) 2004-05-12

Family

ID=23130330

Family Applications (1)

Application Number Title Priority Date Filing Date
IL15890402A IL158904A0 (en) 2001-05-25 2002-05-01 Pirenzepine ophthalmic gel

Country Status (17)

Country Link
US (2) US20040137069A1 (xx)
EP (1) EP1397132A4 (xx)
JP (1) JP2004531569A (xx)
KR (1) KR20040018380A (xx)
CN (1) CN1509172A (xx)
BR (1) BR0210013A (xx)
CA (1) CA2447562A1 (xx)
EC (1) ECSP044862A (xx)
HU (1) HUP0304071A2 (xx)
IL (1) IL158904A0 (xx)
MX (1) MXPA03010655A (xx)
NO (1) NO20035224D0 (xx)
NZ (1) NZ529615A (xx)
PL (1) PL366924A1 (xx)
RU (1) RU2297831C2 (xx)
WO (1) WO2002096418A1 (xx)
ZA (1) ZA200309791B (xx)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2005263577C1 (en) * 2004-07-16 2010-08-26 Proteosys Ag Muscarinic antagonists with PARP and SiR modulating activity as cytoprotective agents
JP4963359B2 (ja) * 2005-01-12 2012-06-27 ロート製薬株式会社 眼局所適用製剤
EP2097044A4 (en) * 2006-12-26 2012-10-10 Quadra Logic Tech Inc DRUG RELIEF IMPLANTS FOR INHIBITING OPTICAL DEFECTS
US10265265B2 (en) 2007-03-15 2019-04-23 Drug Delivery Solutions Limited Topical composition
EP2008651A1 (en) 2007-06-26 2008-12-31 Drug Delivery Solutions Limited A bioerodible patch
NZ598483A (en) 2007-09-07 2013-08-30 Quadra Logic Tech Inc Drug cores for sustained release of therapeutic agents
WO2010083129A2 (en) 2009-01-13 2010-07-22 The Regents Of The University Of California Implantable delivery vehicle for ocular delivery of muscarinic antagonists
EP2632468B1 (en) * 2010-10-25 2017-12-13 University Of Manitoba Therapeutic compositions for diabetic symmetrical polyneuropathy
US9610245B2 (en) 2011-03-14 2017-04-04 Drug Delivery Solutions Limited Ophthalmic composition
RU2635185C2 (ru) * 2013-12-17 2017-11-09 Иван Дмитриевич Захаров Фармацевтический препарат для профилактики и лечения прогрессирующей близорукости
US9421199B2 (en) 2014-06-24 2016-08-23 Sydnexis, Inc. Ophthalmic composition
WO2016172712A2 (en) 2015-04-23 2016-10-27 Sydnexis, Inc. Ophthalmic composition
US11382909B2 (en) 2014-09-05 2022-07-12 Sydnexis, Inc. Ophthalmic composition
US11052094B2 (en) 2015-05-29 2021-07-06 Sydnexis, Inc. D2O stabilized pharmaceutical formulations
CN105663137A (zh) * 2016-01-14 2016-06-15 王真 哌仑西平在制备治疗脓毒症疾病的药物中的应用
EP4112055A1 (en) * 2016-05-25 2023-01-04 Singapore Health Services Pte Ltd Atropine-containing aqueous composition
WO2019087149A1 (en) 2017-11-03 2019-05-09 Novartis Ag Azabicyclo and diazepine derivatives for treating ocular disorders
EP3542788A1 (en) 2018-03-19 2019-09-25 MC2 Therapeutics Limited Topical composition comprising calcipotriol and betamethasone dipropionate
EP3946357A4 (en) * 2019-03-26 2023-04-05 Winsantor, Inc. TOPICAL FORMULATIONS FOR THE TREATMENT OF PERIPHERAL NEUROPATHIES
WO2020251926A1 (en) * 2019-06-10 2020-12-17 Jenivision Inc. Methods and formulations for treating vision disorders

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU188852B (en) * 1983-03-16 1986-05-28 Richter Gedeon Vegyeszeti Gyar Rt,Hu Process for producing thiazolidine derivatives active against gastric ulcer and intestinal ulcer
US4865599A (en) * 1986-08-18 1989-09-12 Houston Biotechnology, Inc. Ophthalmic compositions for treating nerve degeneration
CA1336490C (en) * 1988-06-03 1995-08-01 Paul Michael Iuvone Pharmacological treatment of ocular development
US5122522A (en) * 1989-06-21 1992-06-16 The Trustees Of The University Of Pennsylvania Treatment and control of ocular development
US5360801A (en) * 1989-06-21 1994-11-01 The Trustees Of The University Of Pennsylvania Pharmacological stimulation of eye growth
DE69029734T2 (de) * 1989-06-21 1997-05-28 Univ Pennsylvania Verwendung von Pirenzepine, Telenzepine oder O-Methoxy -sila-hexocyclium zur Herstellung eines Medikaments zur BEHANDLUNG UND REGULIERUNG DER AUGENENTWICKLUNG
US5055302A (en) * 1990-02-22 1991-10-08 Trustees Of The University Of Pennsylvania Neuropeptide control of ocular growth
US5461808A (en) * 1993-02-08 1995-10-31 Fritts; Robert W. Table top backlit display
US5385939A (en) * 1993-04-30 1995-01-31 The Trustees Of The University Of Pennsylvania GABA-ergic modulation of eye growth
US5461052A (en) * 1993-04-30 1995-10-24 The Trustees Of The University Of Pennsylvania Prevention of myopia by tricyclic compounds
US5516808A (en) * 1994-10-27 1996-05-14 Sawaya; Assad S. Topical cellulose pharmaceutical formulation
US5888493A (en) * 1996-12-05 1999-03-30 Sawaya; Assad S. Ophthalmic aqueous gel formulation and related methods
US6164282A (en) * 1999-01-27 2000-12-26 Allergan Sales, Inc. Methods for restoring and/or enhancing accommodation in pseudo phakia

Also Published As

Publication number Publication date
CA2447562A1 (en) 2002-12-05
EP1397132A1 (en) 2004-03-17
WO2002096418A1 (en) 2002-12-05
NZ529615A (en) 2005-07-29
RU2003136735A (ru) 2005-03-27
KR20040018380A (ko) 2004-03-03
JP2004531569A (ja) 2004-10-14
US20040137069A1 (en) 2004-07-15
NO20035224D0 (no) 2003-11-24
PL366924A1 (en) 2005-02-07
ECSP044862A (es) 2004-03-23
MXPA03010655A (es) 2007-06-22
BR0210013A (pt) 2004-08-10
ZA200309791B (en) 2004-10-04
US20060188576A1 (en) 2006-08-24
HUP0304071A2 (hu) 2004-04-28
EP1397132A4 (en) 2006-12-13
CN1509172A (zh) 2004-06-30
RU2297831C2 (ru) 2007-04-27

Similar Documents

Publication Publication Date Title
AU147846S (en) Eyeglasses
HU0401339D0 (en) Novel 4-anilinoquinoline-3-carboxamides
IL158904A0 (en) Pirenzepine ophthalmic gel
EP1387687A4 (en) NEW USE
GB0100762D0 (en) Novel use
GB0115181D0 (en) Novel use
EP1391730A4 (en) GEL CONTAINING A BIOPOLYMER
AU146677S (en) Goggles
AU147847S (en) Eyeglasses
GB0303228D0 (en) Gel
AU147844S (en) Eyeglasses
EP1384783A4 (en) NEW MAXIZYM
AU149769S (en) Eyeglasses
EG23036A (en) Novel pyrrolecarboxamides
GB0218890D0 (en) Spectacles
GB0130151D0 (en) Glass covers
AU149781S (en) Glass
AU147701S (en) Eyeglasses
AU147845S (en) Eyeglasses
EP1426443A4 (en) NEW HUMAN GENE BMCC1
GB0117204D0 (en) Gel dispenser
GB0122061D0 (en) Vision therapy
GB0127840D0 (en) Viscous firelighting gel
GB0120176D0 (en) Shower gel despenser
AU2002253664A1 (en) Biopolymer-containing gel